Entera Bio Ltd. - ENTX

SEC Filings Our ENTX Tweets

About Gravity Analytica

Recent News

10.27.2026 - Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
10.13.2026 - Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
06.22.2026 - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 – the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
06.15.2026 - ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
03.04.2026 - Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
10.21.2025 - October 21, 2025 - October 25, 2025 : The Menopause Society 2025 Annual Meeting (Poster)
10.16.2025 - Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
09.15.2025 - Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congresse Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
09.15.2025 - Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
09.15.2025 - Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress

Entera Bio Ltd. - ENTX

About Gravity Analytica

Recent News

Recent Filings